biostudies-literatureStrikwerda-Brown CNIA NIH HHS975-985https://www.ebi.ac.uk/biostudies/studies/S-EPMC9339146biostudies-literatureUnknown79(10)<h4>Importance</h4>National Institute on Aging-Alzheimer's Association (NIA-AA) workgroups have proposed biological research criteria intended to identify individuals with preclinical Alzheimer disease (AD).<h4>Objective</h4>To assess the clinical value of these biological criteria to identify older individuals without cognitive impairment who are at near-term risk of developing symptomatic AD.<h4>Design, setting, and participants</h4>This longitudinal cohort study used data from 4 independent population-based cohorts (PREVENT-AD, HABS, AIBL, and Knight ADRC) collected between 2003 and 2021. Participants were older adults without cognitive impairment with 1 year or more of clinical observation after amyloid β and tau positron emission tomography (PET). Median clinical follow-up after PET rJAMA neurologyAssociation of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment.PMC9339146P30 AG066444K01 AG053474P01 AG036694R00 AG061238P01 AG003991Breitner JCSChhatwal JPPogossova GGervais VLafaille-Magnan MEPoirier JSpreng NFrenette JLaws SCouture DHoge RMontine TFonov VVogel JKat JLabonte AGordon BAMartins RMohammediyan BSepulcre JRioux PTullo SLois Gomez CMathieu AKazazian CGatchel JCarrier CETeigner EYu EPardilla-Delgado EQuiroz YKhachaturian ZJohnson KACheewakriengkrai LRajah NFerdinand FAppleby MBuckley RDadar MFrappier JDickerson BAisen PAnthal ECraft STaddei KGuzman-Velez EDebacker CDansereau CSoucy JPBedetti CVachon-Presseau EProvost KRentz DSaint-Fort EFMulthaup GBrandt JHobbs DAOzlen HDore VJutten REl-Khoury RFowler CReynolds GBuckley RFChen YEvans ADuclair GOaoo KTardif CNear JDesautels RDufour MDaoust LAGagliardi GEisenberg MCuello CBarkun ASkylar-Scott ITheroux LTuwaig MJohnson KFarzin SGeddes MFaubert AMDauar-Tedeschi MMcSweeney MMadjar CChapleau MCourcot BSager MPREVENT-AD, HABS, and AIBL Research GroupsMorris JRemz JSavard MJean GBreitner JDubuc SSylvain EBenzinger TLSMeyer POCollins LPruessner JVillemagne VLGordon RBlacker DWan KGiles RFontaine DKostopoulos PVila-Castelar CPage VIturia-Medina YJacobs HBinette APVerfaillie SKnopman DVenugopalan VBourgeat PCarmo LMa Nter LMMaruff PPetkova MRowe CCVilleneuve SLeoutsakos JMThomas RPascoal TBenbouhoud FMayrand GPrice JYang HSRosa-Neto PGreco CTam APichet Binette ABohbot VSt-Onge FSperling RLeblond-Baccichet GGagne GSperling RAPishnamazi MOrban PTabrizi SLee TKobe TGauthier SToussaint PJSalaciak AA Lie MJBrown BStrikwerda-Brown CWang SAmariglio REMiron JVallee ILepage CMaltais JRAyranci GLBailly JTremblay-Mercier JMathotaarachchi SMichaud DSchultz AJack CNewbold-Fox HDucharme SDonovan NBeaudry TBellec PHudon LNilsson NPicard CVannini PDas SChakravarty MEtienne PWard LMaillet DFarrell MNair VLeppert ISchultz SFripp JProkopiou PDea DMasters CLMarshall GMorris JCBoutin STariot PRainy-Smith SMahar LGonneaud JfalseAssociation of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment.<h4>Importance</h4>National Institute on Aging-Alzheimer's Association (NIA-AA) workgroups have proposed biological research criteria intended to identify individuals with preclinical Alzheimer disease (AD).<h4>Objective</h4>To assess the clinical value of these biological criteria to identify older individuals without cognitive impairment who are at near-term risk of developing symptomatic AD.<h4>Design, setting, and participants</h4>This longitudinal cohort study used data from 4 independent population-based cohorts (PREVENT-AD, HABS, AIBL, and Knight ADRC) collected between 2003 and 2021. Participants were older adults without cognitive impairment with 1 year or more of clinical observation after amyloid β and tau positron emission tomography (PET). Median clinical follow-up after PET r2022-01-01T00:00:00Z2022 Oct2025-04-18T17:22:27.159Z2025-04-07T04:53:03.547ZS-EPMC93391463590725410.1001/jamaneurol.2022.2379